ABB  Vol.4 No.4 A , April 2013
Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production
Abstract: For many years, the potential of immunoglobulin M (IgM) antibodies was not fully understood because of characteristics different to the well-known immunoglobulin G type like low target affinity, cross reactivity and complex protein structure. In the meanwhile IgMs have been positively evaluated for their use as therapeutic agent in the mucosal environment but also in serum to eradicate upcoming tumor cells and invading antigens. Therefore IgM class of antibodies will play a significant role in clinical applications but also diagnosis in the future. To evaluate the full potential of this kind of antibody molecules large amounts of high quality product will be needed. In this review the focus is set on the biotechnological aspect of producing IgM class antibodies recombinantly in mammalian cells. Current achievements in expression and purification of this molecule are highlighted and compared.
Cite this paper: Mader, A. , Chromikova, V. and Kunert, R. (2013) Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production. Advances in Bioscience and Biotechnology, 4, 38-43. doi: 10.4236/abb.2013.44A006.

[1]   Vollmers, H.P. and Brändlein, S. (2009) Natural antibodies and cancer. New Biotechnology, 25, 294-298. doi:10.1016/j.nbt.2009.03.016

[2]   Collins, C., Tsui, F.W. and Shulman, M.J. (2002) Differential activation of human and guinea pig complement by pentameric and hexameric IgM. European Journal of Immunology, 32, 1802-1810. doi:10.1002/1521-4141(200206)32:6<1802::AID-IMMU1802>3.0.CO;2-C

[3]   Wiersma, E.J., Collins, C., Fazel, S. and Shulman, M.J. (1998) Structural and functional analysis of J chain-deficient IgM. The Journal of Immunology, 160, 5979-5989.

[4]   Irie, R.F., Ollila, D.W., O’Day, S. and Morton, D.L. (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 53, 110- 117. doi:10.1007/s00262-003-0436-1

[5]   Jones, P.C., Sze, L.L., Liu, P.Y., Morton, D.L. and Irie, R.F. (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. Journal of the National Cancer Institute, 66, 249-254.

[6]   Ollert, M.W., David, K., Schmitt, C., Hauenschild, A., Bredehorst, R., Erttmann, R., et al. (1996) Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 93, 4498-4503. doi:10.1073/pnas.93.9.4498

[7]   Vollmers, H.P., O’Connor, R., Müller, J., Kirchner, T. and Müller-Hermelink, H.K. (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Research, 49, 2471-2476.

[8]   Casali, P. and Schettino, E.W. (1996) Structure and function of natural antibodies. Current Topics in Microbiology and Immunology, 210, 167-179. doi:10.1007/978-3-642-85226-8_17

[9]   Horn, M.P., Zuercher, A.W., Imboden, M.A., Rudolf, M.P., Lazar, H., Wu, H., et al. (2010) Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrobial Agents and Chemotherapy, 54, 2338-2344. doi:10.1128/AAC.01142-09

[10]   Ilag, L.L. (2011) Immunoglobulin M as a vaccine adjuvant. Medical Hypotheses, 77, 473-478. doi:10.1016/j.mehy.2011.06.013

[11]   Yang, Q.E. (2009) IgM, not IgG, a key for HIV vaccine. Vaccine, 27, 1287-1288. doi:10.1016/j.vaccine.2008.12.030

[12]   Frutiger, S., Hughes, G.J., Paquet, N., Lüthy, R. and Jaton, J.C. (1992) Disulfide bond assignment in human J chain and its covalent pairing with immunoglobulin M. Biochemistry, 31, 12643-12647. doi:10.1021/bi00165a014

[13]   Niles, M.J., Matsuuchi, L. and Koshland, M.E. (1995) Polymer IgM assembly and secretion in lymphoid and nonlymphoid cell lines: Evidence that J chain is required for pentamer IgM synthesis. Proceedings of the National Academy of Sciences of the United States of America, 92, 2884-2888. doi:10.1073/pnas.92.7.2884

[14]   Brewer, J.W., Randall, T.D., Parkhouse, R.M. and Corley, R.B. (1994) Mechanism and subcellular localization of secretory IgM polymer assembly. The Journal of Biological Chemistry, 269, 17338-17348.

[15]   Racine, R. and Winslow, G.M. (2009) IgM in microbial infections: Taken for granted? Immunology Letters, 125, 79-85. doi:10.1016/j.imlet.2009.06.003

[16]   Metzger, H. (1970) Structure and function of gamma M macroglobulins. Advances in Immunology, 12, 57-116. doi:10.1016/S0065-2776(08)60168-6

[17]   Randall, T.D., King, L.B. and Corley, R.B. (1990) The biological effects of IgM hexamer formation. European Journal of Immunology, 20, 1971-1979. doi:10.1002/eji.1830200915

[18]   Brewer, J.W., Randall, T.D., Parkhouse, R.M. and Corley, R.B. (1994) IgM hexamers? Immunology Today, 15, 165- 168. doi:10.1016/0167-5699(94)90313-1

[19]   Hughey, C.T., Brewer, J.W., Colosia, A.D., Rosse, W.F. and Corley, R.B. (1998) Production of IgM hexamers by normal and autoimmune B cells: Implications for the physiologic role of hexameric IgM. The Journal of Immunology, 161, 4091-4097.

[20]   Reddy, P.S. and Corley, R.B. (1999) The contribution of ER quality control to the biologic functions of secretory IgM. Immunology Today, 20, 582-588. doi:10.1016/S0167-5699(99)01542-X

[21]   Johansen, F.E., Braathen, R. and Brandtzaeg, P. (2000) Role of J chain in secretory immunoglobulin formation. Scandinavian Journal of Immunology, 52, 240-248. doi:10.1046/j.1365-3083.2000.00790.x

[22]   Butler, M. and Meneses-Acosta, A. (2012) Recent advances in technology supporting biopharmaceutical production from mammalian cells. Applied Microbiology and Biotechnology, 96, 885-894. doi:10.1007/s00253-012-4451-z

[23]   Kim, J.Y., Kim, Y.G. and Lee, G.M. (2012) CHO cells in biotechnology for production of recombinant proteins: Current state and further potential. Applied Microbiology and Biotechnology, 93, 917-930. doi:10.1007/s00253-011-3758-5

[24]   De Jesus, M. and Wurm, F.M. (2011) Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. European Journal of Pharmaceutics and Biopharmaceutics, 78, 184-188. doi:10.1016/j.ejpb.2011.01.005

[25]   Kunert, R., Wolbank, S., Stiegler, G., Weik, R. and Katinger, H. (2004) Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Research and Human Retroviruses, 20, 755-762. doi:10.1089/0889222041524571

[26]   Gilmour, J.E., Pittman, S., Nesbitt, R. and Scott, M.L. (2008) Effect of the presence or absence of J chain on expression of recombinant anti-Kell immunoglobulin M. Transfusion Medicine and Hemotherapy, 18, 167-174. doi:10.1111/j.1365-3148.2008.00853.x

[27]   Tchoudakova, A., Hensel, F., Murillo, A., Eng, B., Foley, M., Smith, L., et al. (2009) High level expression of functional human IgMs in human PER.C6 cells. MAbs, 1, 163-171.

[28]   Kuczewski, M., Schirmer, E., Lain, B. and Zarbis-Papastoitsis, G. (2011) A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnology Journal, 6, 56-65. doi:10.1002/biot.201000292

[29]   Havenga, M.J., Holterman, L., Melis, I., Smits, S., Kaspers, J., Heemskerk, E., et al. (2008) Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: High yield and preserved bioactivity. Biotechnology and Bioengineering, 100, 273-283. doi:10.1002/bit.21757

[30]   Wolbank, S., Kunert, R., Stiegler, G. and Katinger, H. (2003) Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. Journal of Virology, 77, 4095-4103. doi:10.1128/JVI.77.7.4095-4103.2003

[31]   Azuma, Y., Ishikawa, Y., Kawai, S., Tsunenari, T., Tsunoda, H., Igawa, T., et al. (2007) Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma. Clinical Cancer Research, 13, 2745-2750. doi:10.1158/1078-0432.CCR-06-2919

[32]   Tarköy, M., Wyss, M. and Rudolf, M.P. (2010) A comparative characterization of dipentameric (IgM)(2) and pentameric IgM species present in preparations of a monoclonal IgM for therapeutic use. Journal of Pharmaceutical and Biomedical Analysis, 51, 1084-1090. doi:10.1016/j.jpba.2009.11.003

[33]   Harris, R.J., Shire, S.J. and Winter, C. (2004) Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Development Research, 61, 137-154. doi:10.1002/ddr.10344

[34]   Vorauer-Uhl, K., Wallner, J., Lhota, G., Katinger, H. and Kunert, R. (2010) IgM characterization directly performed in crude culture supernatants by a new simple electrophoretic method. Journal of Immunological Methods, 359, 21-27.

[35]   Steindl, F., Jungbauer, A., Wenisch, E., Himmler, G. and Katinger, H. (1987) Isoelectric precipitation and gel chromatography for purification of monoclonal IgM. Enzyme and Microbial Technology, 9, 361-364.

[36]   Gagnon, P., Hensel, F. and Richieri, R. (2007) Recent advances in the purification of IgM monoclonal antibodies. 3rd Wilbio Conference on Purification of Biological Products, Waltham, 24-26 September 2007.

[37]   Gagnon, P. (2009) Monoclonal antibody purification with hydroxyapatite. New Biotechnology, 25, 287-293.

[38]   Tscheliessnig, A., Ong, D., Lee, J., Pan, S., Satianegara, G., Schriebl, K., et al. (2009) Engineering of a two-step purification strategy for a panel of monoclonal immunoglobulin M directed against undifferentiated human embryonic stem cells. Journal of Chromatography A, 1216, 7851-7864.

[39]   Gagnon, P., Hensel, F., Lee, S. and Zaidi, S. (2011) Chromatographic behavior of IgM: DNA complexes. Journal of Chromatography A, 1218, 2405-2412.

[40]   Lee, J., Gan, H.T., Latiff, S.M.A., Chuah, C., Lee, W.Y., Yang, Y.-S., et al. (2012) Principles and applications of steric exclusion chromatography. Journal of Chromatography A, 1270, 162-170.

[41]   Hanala, S. (2012) The new ParaDIgm: IgM from bench to clinic: November 15-16, 2011, Frankfurt, Germany. Multi- Agent-Based Simulation (MABS), 4, 555-561.